Surveillance effective for TP53-mutation carriers

Sidaway, Peter

doi:10.1038/nrclinonc.2016.137

In Brief
Published: 23 August 2016

Genetics

Surveillance effective for TP53-mutation carriers

Peter Sidaway

Nature Reviews Clinical Oncology volume 13, page 590 (2016)Cite this article

450 Accesses
Metrics details

Subjects

Access through your institution

Buy or subscribe

Individuals with Li–Fraumeni syndrome, who harbour pathogenic germline TP53 mutations, have a substantially increased risk of developing cancer than those with wild-type TP53. Data from a newly published study confirm that regular surveillance of these individuals for asymptomatic cancers is warranted. In a prospective study, with a cohort of 89 individuals with Li– Fraumeni syndrome, 32% of patients undergoing regular surveillance had asymptomatic tumours detected during the surveillance period, compared with 88% of patients not on surveillance requiring treatment for symptomatic tumours. The need for regular surveillance of individuals with Li– Fraumeni syndrome was further confirmed by the superior 5-year overall survival outcomes of individuals in the surveillance group (88.8%) compared with those who chose not to undergo surveillance (59.6%).

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

Purchase on SpringerLink
Instant access to full article PDF

Buy now

Prices may be subject to local taxes which are calculated during checkout

References

Villani, A. et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol. http://dx.doi.org/10.1016/S1470-2045(16)30249-2 (2016)

Download references

Authors